Briefing
Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.
Fewer patients in the ctDNA-guided arm received adjuvant chemotherapy (15.3% vs 27.9%; odds ratio 2.14; P=0.002). ctDNA-guided management was non-inferior for 2-year RFS (93.5% vs 92.4%; difference 1.1%, 95% CI -4.1% to 6.2%). After chemotherapy, 3-year RFS in ctDNA-positive patients was 86.4%; without chemotherapy, 3-year RFS in ctDNA-negative patients was 92.5% (96.7% in clinically low-risk disease).
- Design: LBA
- n: 455 randomized (302 ctDNA-guided, 153 standard management)
- Assay: tumor-informed Safe-SeqS (named in the abstract)